Overview

Study Evaluating AGG-523 in Subjects With Osteoarthritis

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of AGG-523 administration on biomarkers related to osteoarthritis. Safety and tolerability of AGG-523 will also be assessed.
Phase:
Phase 1
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer